Cook Biotech Incorporated Release: First U.S. Drug-Eluting Stent Trial To Treat Peripheral Arterial Disease Enrolls First Patient At Stanford University Medical Center
10/19/2005 5:13:06 PM
STANFORD, Calif.--(BUSINESS WIRE)--March 23, 2005--
New Treatment Could Benefit Millions Who Suffer From Seriously Under-Diagnosed Disease
The first patient was treated Monday at Stanford University Medical Center in a landmark clinical trial evaluating a drug-coated stent from Cook Incorporated for peripheral arterial disease (PAD), a serious medical condition that affects more than 10 million Americans each year.
The trial is the first U.S. trial ever to test whether drug-eluting stents, which have shown clinical success in treating coronary artery disease, can have similar benefits in treating arteries outside the heart. The elderly female patient was treated by a team of doctors led by Michael D. Dake, M.D., Professor and Chairman of the Department of Radiology at the University of Virginia Health System and national principal investigator, and Daniel Sze, M.D., Associate Professor of Radiology at Stanford University Medical Center and principal investigator for the trial at Stanford.